Compare Johnson & Johnson (JNJ) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs KLA Corp. — how do they compare? Johnson & Johnson trades at $250.82 (market cap $598.96B), while KLA Corp. trades at $216.43 (market cap $271.18B). The key difference: Johnson & Johnson is far larger — about 2.2× KLA Corp.'s market cap, and Johnson & Johnson pays the higher dividend (2.15%). Which is the better fit depends on your goals.
| JNJ | KLAC | |
|---|---|---|
Market Cap | $598.96B | $271.18B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $301.71 |
52-Week Low | $164.36 | $84.39 |
Enterprise Value | $631.90B | $272.37B |
Dividend Yield | 2.15% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $250.61, down 0.96% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $2.90 versus $2.84 expected, and revenue growth of 6.6% year-over-year. The stock shows robust profitability with a net income margin of 21.48% and ROE of 26.42%, supported by consistent dividend payments including the recent $1.34 per share declared for H1-2026.
JNJ presents a favorable investment case with analyst consensus price target of $279.33 implying ~11% upside, though rising debt-to-asset ratio to 24.06% in 2025 and volatile cash flow trends pose risks. The healthcare giant's diversified portfolio and raised full-year guidance underpin long-term stability, but investors should monitor execution amid competitive and regulatory pressures.
KLA Corporation (KLAC) trades at $217.56, up 2.26% today, showing strong momentum after recent earnings beats. The stock maintains bullish technical signals with RSI levels indicating potential oversold conditions. Fundamentally, KLAC demonstrates robust profitability with 35.66% net income margin and consistent revenue growth, though valuation ratios remain elevated. Recent corporate actions include a 1:10 stock split and $2.30 dividend payment, reflecting management confidence.
KLAC presents a compelling growth story with dominant semiconductor process control positioning, but faces valuation concerns and sector volatility risks. Analyst consensus remains bullish with $242.49 price target, though near-term headwinds from semiconductor market correction require careful monitoring. The company's strong cash flow generation and AI-driven equipment demand support long-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
